Understanding how brain tumors interact with the immune system
Project 2: Deciphering the Dynamic Evolution of the Tumor-Immune Interface
This study is looking at new ways to treat glioblastoma, a serious brain cancer, by combining chemotherapy with treatments that help boost your immune system, to see if this can improve how well patients respond to the treatment and fight the tumor.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Massachusetts Institute of Technology NIH-funded |
| Lab location | 1 site (Cambridge, United States) |
| Project ID | NIH-11186260 on NIH RePORTER |
What this research studies
This research investigates glioblastoma, a deadly brain cancer, and explores innovative treatment strategies that combine chemotherapy with immune system boosters. By analyzing how these treatments affect the immune response and the types of tumor antigens presented, the research aims to improve patient outcomes. The approach includes in situ vaccination techniques that could potentially enhance the body's ability to fight the tumor and develop lasting immunity. Patients may be monitored for changes in their immune response and tumor characteristics throughout the treatment process.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with glioblastoma who are seeking innovative treatment options.
Not a fit: Patients with other types of brain tumors or those who are not diagnosed with glioblastoma may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma, potentially improving survival rates and quality of life for patients.
How similar studies have performed: Previous research has shown promise in using immunotherapy combined with chemotherapy for various cancers, suggesting potential success for this novel approach in glioblastoma.
Where this research is happening
Cambridge, United States
- Massachusetts Institute of Technology — Cambridge, United States (Active)
Researchers
- Principal investigator: White, Forest M — Massachusetts Institute of Technology
- Study coordinator: White, Forest M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.